The Moo'D Study: protocol for a randomised controlled trial of A2 beta-casein only versus conventional dairy products in women with low mood.
Beta-casein
Dairy
Depression
Gut microbiota
Inflammation
Mental disorders
Milk
Psychiatry
Psychological distress
Randomised controlled trial
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
11 Dec 2021
11 Dec 2021
Historique:
received:
03
02
2021
accepted:
09
11
2021
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Beta-casein is a major protein in cow's milk, of which A1 and A2 are the most frequent variants. Recent evidence implicates A1 beta-casein consumption in mechanisms that are of potential importance to mental health, yet its possible effects on psychological endpoints remains unknown. The primary aim of the study is to evaluate the comparative effects of consumption of dairy products containing A2 beta-casein versus conventional dairy (i.e. containing both A1 and A2 beta-casein) on symptoms of psychological distress in women with low mood. 'The Moo'D Study' is a 16-week, superiority, 1:1 parallel group, triple-blinded, randomised controlled trial. Ninety women with low mood (Patient Health Questionnaire score ≥ 5) will be randomised to consume either A2 beta-casein only or conventional dairy products. The primary outcome, symptoms of psychological distress, will be measured by the 21-item Depression, Anxiety and Stress Scale. Secondary outcomes will include symptoms of depression, anxiety and stress, severity of low mood, cognition, gut microbiota composition, gut symptomatology, markers of immune function, gut inflammation, systemic metabolites, endothelial integrity and oxidative stress, body composition, perceived wellbeing, sleep, quality of life, resource use and cost-effectiveness. This study will advance our understanding of the possible impact of milk proteins on psychological distress in women as well as elucidate mechanisms underpinning any association. Given dairy products form a substantial component of traditional and Western diets, the implications of these findings are likely to be of clinical and public health importance. The trial protocol has been prospectively registered with the Australia and New Zealand Clinical Trials Registry, ACTRN12618002023235 . Registered on 17 December 2018.
Sections du résumé
BACKGROUND
BACKGROUND
Beta-casein is a major protein in cow's milk, of which A1 and A2 are the most frequent variants. Recent evidence implicates A1 beta-casein consumption in mechanisms that are of potential importance to mental health, yet its possible effects on psychological endpoints remains unknown. The primary aim of the study is to evaluate the comparative effects of consumption of dairy products containing A2 beta-casein versus conventional dairy (i.e. containing both A1 and A2 beta-casein) on symptoms of psychological distress in women with low mood.
METHODS
METHODS
'The Moo'D Study' is a 16-week, superiority, 1:1 parallel group, triple-blinded, randomised controlled trial. Ninety women with low mood (Patient Health Questionnaire score ≥ 5) will be randomised to consume either A2 beta-casein only or conventional dairy products. The primary outcome, symptoms of psychological distress, will be measured by the 21-item Depression, Anxiety and Stress Scale. Secondary outcomes will include symptoms of depression, anxiety and stress, severity of low mood, cognition, gut microbiota composition, gut symptomatology, markers of immune function, gut inflammation, systemic metabolites, endothelial integrity and oxidative stress, body composition, perceived wellbeing, sleep, quality of life, resource use and cost-effectiveness.
DISCUSSION
CONCLUSIONS
This study will advance our understanding of the possible impact of milk proteins on psychological distress in women as well as elucidate mechanisms underpinning any association. Given dairy products form a substantial component of traditional and Western diets, the implications of these findings are likely to be of clinical and public health importance.
TRIAL REGISTRATION
BACKGROUND
The trial protocol has been prospectively registered with the Australia and New Zealand Clinical Trials Registry, ACTRN12618002023235 . Registered on 17 December 2018.
Identifiants
pubmed: 34895297
doi: 10.1186/s13063-021-05812-6
pii: 10.1186/s13063-021-05812-6
pmc: PMC8665310
doi:
Substances chimiques
Biomarkers
0
Caseins
0
Milk Proteins
0
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
899Informations de copyright
© 2021. The Author(s).
Références
BMC Med. 2017 Jan 30;15(1):23
pubmed: 28137247
Mol Neurobiol. 2018 May;55(5):4195-4206
pubmed: 28612257
J Appl Genet. 2007;48(3):189-98
pubmed: 17666771
Neuro Endocrinol Lett. 2008 Feb;29(1):117-24
pubmed: 18283240
Mol Psychiatry. 2019 Jul;24(7):965-986
pubmed: 30254236
Eur J Nutr. 2014 Jun;53(4):1039-49
pubmed: 24166511
Annu Rev Psychol. 2020 Jan 4;71:49-78
pubmed: 31567042
Neurosci Biobehav Rev. 2014 Sep;45:46-62
pubmed: 24858007
Psychooncology. 2016 Jul;25(7):857-64
pubmed: 26525165
Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):281-283
pubmed: 28276814
J Clin Microbiol. 2007 Sep;45(9):2761-4
pubmed: 17626177
Psychother Psychosom. 2015;84(3):167-76
pubmed: 25831962
Lipids Health Dis. 2007 Sep 25;6:25
pubmed: 17894873
Am J Psychiatry. 1984 Sep;141(9):1059-66
pubmed: 6087690
Int J Food Sci Nutr. 2014 Sep;65(6):720-7
pubmed: 24649921
Diabetologia. 1999 Mar;42(3):292-6
pubmed: 10096780
Nutr J. 2016 Apr 02;15:35
pubmed: 27039383
Peptides. 2014 Jun;56:68-71
pubmed: 24657283
Nutr Neurosci. 2000;3(1):57-72
pubmed: 27416160
N Z Med J. 2003 Jan 24;116(1168):U295
pubmed: 12601419
Adv Nutr. 2018 May 1;10(suppl_2):S239-S250
pubmed: 31089732
BMC Gastroenterol. 2007 May 03;7:16
pubmed: 17475020
Eur J Clin Nutr. 2014 Sep;68(9):994-1000
pubmed: 24986816
Alcohol. 2015 Feb;49(1):65-70
pubmed: 25559494
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Nutrients. 2015 Aug 31;7(9):7285-97
pubmed: 26404362
J Psychosom Res. 2000 Jun;48(6):555-60
pubmed: 11033374
Nutr Res Rev. 2014 Dec;27(2):232-41
pubmed: 25268900
Nutrition. 1995 Nov-Dec;11(6):751-4
pubmed: 8719134
Age (Dordr). 2015 Jun;37(3):9782
pubmed: 25903286
Aliment Pharmacol Ther. 2016 Oct;44(7):693-703
pubmed: 27492648
Adv Nutr. 2017 Sep 15;8(5):739-748
pubmed: 28916574
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):232-8
pubmed: 21108982
Nutr Metab Cardiovasc Dis. 2020 Jun 9;30(6):872-888
pubmed: 32409275
Br J Radiol. 1992 Oct;65(778):895-900
pubmed: 1422663
BMC Public Health. 2018 May 22;18(1):599
pubmed: 29783983
Proc Nutr Soc. 2017 Aug;76(3):203-212
pubmed: 28629483
PLoS One. 2015 Feb 06;10(2):e0116820
pubmed: 25658103
Front Psychiatry. 2019 Feb 11;10:34
pubmed: 30804820
Int J Food Sci Nutr. 2020 Feb;71(1):36-49
pubmed: 31154909
JAMA. 1996 Aug 28;276(8):637-9
pubmed: 8773637
EMBO Rep. 2016 Sep;17(9):1245-9
pubmed: 27491723
Aust N Z J Public Health. 2000 Dec;24(6):576-83
pubmed: 11215004
Proc Nutr Soc. 2017 Nov;76(4):427-436
pubmed: 28942748
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Hum Psychopharmacol. 2011 Dec;26(8):560-7
pubmed: 22095836
PLoS One. 2019 Oct 9;14(10):e0222768
pubmed: 31596866
Psychiatry Res. 2015 Dec 15;230(2):537-44
pubmed: 26453120
Nutr J. 2017 Oct 25;16(1):72
pubmed: 29070042
Biomed Biochim Acta. 1990;49(11):1203-7
pubmed: 1965564
Acta Psychiatr Scand. 2013 May;127(5):344-54
pubmed: 22900942
Personal Ment Health. 2015 Nov;9(4):250-7
pubmed: 26314385
BMC Gastroenterol. 2011 Mar 16;11:22
pubmed: 21410934
Arch Clin Neuropsychol. 2009 Mar;24(2):165-78
pubmed: 19395350
Nutr J. 2016 Sep 29;15(1):82
pubmed: 27680716
Gut. 2016 Dec;65(12):1930-1937
pubmed: 27459152
Crit Rev Food Sci Nutr. 2020;60(21):3653-3668
pubmed: 31868529
Science. 2006 Jun 2;312(5778):1355-9
pubmed: 16741115
Psychother Psychosom. 2015;84(6):384-6
pubmed: 26402222
Br J Clin Psychol. 2005 Jun;44(Pt 2):227-39
pubmed: 16004657